Healio
Healio

Read more

October 13, 2020
1 min read
Save

Nine important updates for World Thrombosis Day

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

World Thrombosis Day is observed Oct. 13.

The campaign is intended to raise awareness of the condition, including its causes, risk factors, symptoms, and prevention and treatment strategies.

Deep Vein Thrombosis
Source: Adobe Stock.

In conjunction with this observance, Healio and HemOnc Today present nine important updates in thrombosis treatment, surveillance and risk prediction.

  1. Rivaroxaban (Xarelto, Janssen) reduced risk for recurrent venous thromboembolism compared with warfarin among patients with VTE and obesity. Read more.
  2. Trauma patients who underwent emergency general surgery appeared to have a twofold higher risk for VTE than patients who underwent elective surgery. Read more.
  3. ASH has convened a multidisciplinary panel that will develop guidelines on the role of anticoagulation for patients with COVID-19. Read more.
  4. A case series showed twice the prevalence of pulmonary embolism among patients with COVID-19 admitted to the ICU than patients admitted to the ICU the same time in 2019. Read more.
  5. Thromboprophylaxis with low-molecular-weight heparin alone appeared noninferior to thromboprophylaxis combined with graduated compression stockings for individuals at moderate or high risk for VTE after elective surgery. Read more.
  6. More than one in 10 patients with lymphoma who underwent chimeric antigen receptor T-cell therapy developed new VTE. Researchers characterized this as a “significant incidence.” Read more.
  7. Children with peripherally inserted central catheters demonstrated a significantly higher risk for VTE than children with centrally inserted tunneled lines. Read more.
  8. Black patients with cancer appeared to be at a higher risk for cancer-associated VTE than patients of other races. Read more.
  9. Treatment of VTE with oral apixaban was noninferior to subcutaneous dalteparin (Fragmin, Pfizer), without increasing major bleeding risk. Read more.
Sources/Disclosures

Collapse
Source:

Healio Coverage

Read more about

hematology
thrombosis
rivaroxaban
venous thromboembolism
covid-19
coronavirus
pulmonary embolism
graduated compression hosiery
low-molecular-weight heparin
car t-cell therapy
racial disparity
dalteparin
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

 

Related Content